NEP INTERLONG(08329.HK): Proposed Investment in Jinbaihui Bio to Enter Early Tumour Screening Sector
NewTimeSpace News: Shenzhen Neptunus Interlong Bio-Technique Company Limited (08329.HK) announced that it intends to acquire partial equity interests in Shenzhen Jinbaihui Biotechnology Co., Ltd., either through subscription of new shares or transfer of existing shares. The Group will leverage the sales network of its holding company and Jinbaihui’s exclusive proprietary technology platform for joint business cooperation. Jinbaihui holds China’s first miRNA-based colorectal cancer detection product, which is also the country’s first Class III gene-based colorectal cancer in vitro diagnostic medical device.
NewTimeSpace News: Shenzhen Neptunus Interlong Bio-Technique Company Limited (08329.HK) released an inside information announcement on 25 June 2026 regarding its proposed equity investment.
The Company plans to take a partial stake in Jinbaihui Bio by way of new share issuance or transfer of existing shares, and jointly conduct commercial operations by integrating the sales resources of its holding entity and Jinbaihui’s exclusive proprietary technology platform. Should the cooperation be successfully concluded, the Group will further expand its market reach and cultivate new revenue growth drivers.
Jinbaihui Bio focuses on early diagnosis and screening of malignant tumours, owning a full industrial chain covering R&D, manufacturing, sales of diagnostic reagents & instruments, and third-party medical laboratory testing services. It has built a proprietary microRNA (miRNA) technology platform and developed China’s first miRNA-based colorectal cancer detection assay, the first domestic Class III gene-based in vitro diagnostic device for colorectal cancer screening.
Up to now, Jinbaihui has obtained more than ten authorised domestic and foreign invention patents. Its colorectal, gastric and nasopharyngeal cancer detection products have secured CE-IVD certification for the European market, while pipelines covering breast, pancreatic, prostate, bladder and pan-cancer screening products are under continuous development.
As at the date of this announcement, the Group has signed a non-binding letter of intent for the investment, yet no legally binding investment agreement has been executed.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
